03/17/2021

CMS assigns J9316 as the permanent J-Code for Genentech's PHESGO®, effective 1/1/21

CMS assigned J9316 as the permanent J-Code for PHESGO^®, effective 1/1/21. The code is applicable for both the loading and maintenance doses and billable units are per 10mg.

PHESGO contains pertuzumab, trastuzumab, and hyaluronidase in the following doses and concentrations:

• Loading Dose: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL in a single-dose vial
• Maintenance Dose: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase per 10 mL in a single-dose vial

For CMS billing purposes, there are 1,800 mg of combined pertuzumab and trastuzumab in the loading dose (180 units) and 1,200 mg of combined pertuzumab and trastuzumab in the maintenance dose (120 units). Individual payers may have different preferences for billing Phesgo. Check with your local payers for specific information.

Should you have any questions about dosing, ordering, or billing please contact your local Genentech Field Reimbursement Manager.

Brian Williams 
Portfolio Field Reimbursement Manager - Michigan
Immunology I Oncology | Respiratory | Ophthalmology
Genentech, Inc, a member of the Roche Group 
Cell: 734 - 776 - 6462 
Fax: 201- 831- 2843

Visit https://www.gene.com/medical-professionals/medicines to access the Package Insert for any Genentech product.

For Coverage and Reimbursement Resources: https://www.genentech-pro.com/